Interestingly, a missense mutation of ARF1 (p.L148P), identified in a metastatic GIST tumor, was further verified in a relapsed GIST tumor of the test cohort, suggesting its potential role in GIST progression and therapeutic resistance. This evidence concerns the gene ARF1 and gastrointestinal stromal tumor.